SCHEMBL4566697

SCHEMBL4566697

COc1ccc(CN(C)c2cc3c(cn2)cc(-c2cc(N)c(F)cc2F)c(=O)n3C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.39
SRC P12931 4/20 0.39
ALDH1A1 P00352 1/20 0.37
ADORA2A P29274 1/20 0.36
BTK Q06187 1/20 0.35
FGFR4 P22455 2/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
BRD4 O60885 1/20 0.34
DHFR P00374 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
LYN P07948 1/20 0.33
KDM4E B2RXH2 1/20 0.33
RIPK2 O43353 1/20 0.33
NOD2 Q9HC29 1/20 0.33
CHRNA7 P36544 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062666 0.93 FGFR1 (0.38) FGFR1SRCALDH1A1ADORA2ABTK
SCHEMBL5057701 0.92 FGFR1 (0.43) FGFR1SRCALDH1A1ADORA2ABTK
SCHEMBL4565918 0.91 FGFR1 (0.37) FGFR1SRCALDH1A1ADORA2ABTK
SCHEMBL15006322 0.90 BTK (0.44) SRCALDH1A1ADORA2ABTKLYN
SCHEMBL14999907 0.83 BTK (0.41) SRCALDH1A1BTKLYN
SCHEMBL5063032 0.82 FGFR1 (0.45) FGFR1SRCALDH1A1ADORA2AFGFR4
SCHEMBL14999870 0.82 FGFR4 (0.37) SRCALDH1A1ADORA2ABTKFGFR4
SCHEMBL14999841 0.82 BTK (0.41) SRCALDH1A1BTKFGFR4LYN
SCHEMBL14999919 0.82 FGFR4 (0.37) FGFR1SRCALDH1A1ADORA2ABTK
SCHEMBL15289526 0.80 ALDH1A1 (0.42) ALDH1A1ADORA2ADHFRHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3722296-A2 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC (US) 2020-10-14 EP disclosed
EP-3366293-B1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2020-03-11 EP disclosed
EP-3366293-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC (US) 2018-08-29 EP disclosed
EP-2858646-B1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2017-12-20 EP disclosed
US-20150320759-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC 2015-11-12 US disclosed
US-8461179-B1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2013-06-11 US disclosed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320759-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES NME1, DCK, NME2 FGFR1 376/4885SRC 715/4885ALDH1A1 2118/4885
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 FGFR1 577/4885SRC 417/4885ALDH1A1 1389/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR1 577/4885SRC 417/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.